Current investments

We do not have any companies open for investments at the moment. Sign up to receive an email once something new is coming up.

Completed investments

Encare AB

Encare has developed a cloud-based software solution that helps hospitals follow best practices during surgery, reducing complications, increasing patient satisfaction, and lowering costs for healthcare providers.

Read more

Conceptual medical image of interconnected neurons cells with electrical pulses.

Pharmnovo AB

PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.

Read more

Capitainer AB

Capitainer offers a more convenient and cost-efficient way to take blood samples. The company’s products are designed for home sampling and deliver an exact amount of blood, which is essential to get accurate results.

Read more

NEOGAP Therapeutics AB

NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.

Read more

Exits

Cartana

Cartana’s patent-applied research tool revolutionizes the possibility of analyzing tissue samples, providing pharmaceutical companies with important information in their quest for new treatments.

Read more

Inhalation Sciences

Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.

Read more

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Read more

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more